Posted by Michael Wonder on 12 Feb 2019
Catalyst Pharma sees net price of drug, once free, topping $300,000
12 February 2019 - Catalyst Pharmaceuticals said on Monday that it expects its drug for a rare disease, which had long been available to patients for free, will cost more than $300,000 per year including rebates to insurers and other discounts.
The drug, Firdapse, is used to treat Lambert-Eaton myasthenic syndrome, a rare neuromuscular disorder.
U.S. Senator Bernie Sanders sent a letter to Catalyst last week asking the company to justify its pricing.
